Keyphrases
Antimicrobial Resistance
94%
India
84%
Antibiotics
74%
Antibiotic Use
49%
Antibiotic Resistance
48%
Low-middle Income Countries
35%
COVID-19
33%
Antimicrobial
28%
United States
23%
Confidence Interval
21%
Meta-analysis
19%
Escherichia Coli
19%
Carbapenem Resistance
19%
Systematic Meta-analysis
18%
Klebsiella Pneumoniae (K. pneumoniae)
17%
World Health Organization
17%
Third-generation Cephalosporins
15%
Odds Ratio
14%
Risk Factors
14%
COVID-19 Pandemic
14%
Antibiotic Overuse
12%
Hospital-acquired Infection
12%
High-income Countries
12%
Antimicrobial Stewardship
12%
Sales Data
12%
Antimicrobial Stewardship Program
12%
Pharmaceutical Sales
11%
Faropenem
11%
Point Prevalence Survey
11%
Invasive Isolates
11%
Neonatal Intensive Care Unit
11%
Antimicrobial Use
11%
Diagnostic Performance
11%
Antibiotic Prophylaxis
11%
Cross-resistance
11%
Retrospective Observational Study
11%
Healthcare Settings
11%
Blood Culture
10%
New Antibiotics
10%
Infectious Diseases
10%
Antibiotic Efficacy
10%
Antibiotic Prescribing
10%
Cephalosporin Resistance
10%
Central Line-associated Bloodstream Infection (CLABSI)
9%
Essential Medicines
9%
Low-income
9%
Middle-income Countries
9%
Staphylococcus Aureus
9%
Epidemiology
9%
Tertiary Care Hospital
9%
Medicine and Dentistry
Antibiotic Resistance
71%
Antibiotics
64%
Infection
46%
Low and Middle Income Countries
33%
Severe Acute Respiratory Syndrome Coronavirus 2
32%
Antiinfective Agent
28%
Prevalence
24%
Carbapenem
23%
COVID-19
22%
Observational Study
20%
Pathogen
17%
Systematic Review
15%
Meta-Analysis
15%
Primary Health Care
14%
Carbapenem Derivative
14%
Tertiary Care
13%
Intensive Care Unit
13%
Public Health
12%
Cohort Effect
12%
Faropenem
11%
Cross Resistance
11%
Neonatal Intensive Care Unit
11%
Antibiotic Prophylaxis
11%
Hospital Infection
11%
Bloodstream Infection
11%
Odds Ratio
10%
Infectious Disease
9%
Logistic Regression Analysis
9%
Retrospective Study
8%
Escherichia coli
8%
Neonatal Sepsis
8%
Klebsiella pneumoniae
8%
Randomized Controlled Trial
8%
Infection Control
7%
In Vitro
7%
Infection Prevention
7%
Surgical Technique
7%
Health Care
7%
Quinolone Derivative
7%
Gram-Negative Bacteria
7%
Essential Medicines
7%
Antimicrobial Agent
6%
Third Generation Cephalosporin
6%
Prostate Biopsy
6%
Comorbidity
6%
Healthcare Associated Infection
6%
Surgical Infection
5%
Quality Improvement
5%
Needle Biopsy
5%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antibiotics
100%
Antimicrobial Resistance
71%
Infection
70%
Carbapenem
34%
Antiinfective Agent
29%
Diseases
27%
Prevalence
23%
Coronavirinae
22%
Infectious Agent
21%
Bloodstream Infection
19%
Carbapenem Derivative
16%
SARS Coronavirus
15%
Klebsiella pneumoniae
15%
Essential Medicines
14%
Observational Study
13%
Retrospective Study
12%
Escherichia coli
12%
Fropenem
11%
Cross-Resistance
11%
Third Generation Cephalosporin
9%
Pseudomonas aeruginosa
9%
Pandemic
8%
Colistimethate
7%
Staphylococcus Aureus
7%
Healthcare Associated Infection
7%
Antimicrobial Agent
7%
Acinetobacter Baumannii
7%
Gram Negative Bacterium
7%
Antibiotic Agent
6%
Methicillin-Resistant Staphylococcus Aureus
6%
Quinolone Derivative
6%
Gentamicin
6%
Ampicillin
6%
Defined Daily Dose
6%
Vancomycin
6%
Hydroxychloroquine
5%
Extended Spectrum Beta Lactamase Producing Escherichia Coli
5%
Nucleic Acid
5%
Fungemia
5%
Molecular Epidemiology
5%
Antibody Conjugate
5%
Hemodialysis
5%
Lateral Flow Assay
5%
Hypoxemia
5%
Cancer Chemotherapy
5%
Streptococcus Group A
5%
Nanoparticle
5%
Antibiotic-Resistant Bacteria
5%
Escherichia Coli Pneumonia
5%
Meticillin
5%